Examples of using Interim analysis in English and their translations into Greek
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Official/political
-
Computer
Interim analysis.
Data from first interim analysis.
Interim analysis of the European study 14701.
Data from first interim analysis 25 July 2018.
Survival continued to be followed after the interim analysis.
Prespecified interim analysis Minimum follow-up: 13.2 months.
The overall survival(OS) data were not mature at the time of the interim analysis.
Pre-planned Interim Analysis(35% OS maturity)(n=153).
CI= confidence interval a The Phase 3 study ALSYMPCA was stopped for efficacy after the interim analysis.
The Interim Analysis report of OS should be submitted by.
Pivotal efficacy data were based on an interim analysis at 12 months after treatment.
The interim analysis for OS was conducted when 331 events were observed.
PFS and ORR results are reported from an interim analysis at a median follow-up of 11 months.
This interim analysis showed a TTP risk reduction of 45%(95% CI; 29-57%), p< 0.0001.
Results from this analysis were consistent with those from the interim analysis(Table 3, Figure 4).
At the time of interim analysis, 22 out of 24 patients(92%) were alive.
The length of treatment ranged from 74 to 474 days(median 250 days)at the time of the interim analysis.
At the time of a Study CS11 interim analysis, 61 out of 65 patients(94%) were alive.
An interim analysis of OS had not taken place at the time of the ORR analysis. .
The vaccine efficacy against B-CAP observed at the interim analysis is presented below(table 2).
Interim analysis indicates that the effect was sustained up to one year of treatment.
Figure 1: Kaplan-Meier Plot of Time to Relapse- Interim Analysis(Intent-to-Treat Interim Analysis Set).
The OS interim analysis was performed at 51% for the total number of planned events.
Exposure numbers were influenced by the study stopping at a pre-determined number of relapses based on the interim analysis.
Timing of any planned interim analysis and the number of subjects planned to be enrolled;
In Study CS11 all patients received Spinraza, with the length of treatment ranging from 65 to 592 days(median 289 days)at the time of interim analysis.
In an interim analysis of the 2007 to 2014 study period, out of 1,355,720 study individuals, 392,677 received ZOSTAVAX.
The study was un-blinded after this planned interim analysis of OS had crossed the pre-specified efficacy boundary.
The interim analysis results indicated that it failed to achieve statistical significance in any evaluated efficacy endpoint.
The submission is based on the results of the first pre-specified interim analysis of the pivotal Phase 3 trial TOURMALINE-MM1.